Global Regulatory Agencies Support Use of Dopamine Transporter Neuroimaging in Clinical Trials Targeting Early Parkinson’s Disease

Diane Stephenson¹, Klaus Romero¹, Daniela Conrado¹, Jesse M Cedarbaum⁴, Derek Hill⁹, Debra Babcock¹³, Massimo Bani¹⁷, Peter Basseches¹², Malidi Ahamadi¹², Vikram Sinha¹², Chao Chen¹⁹, Jamie Eberling¹⁰, Karleyton Evans⁶, Maurizio F Facheris², Jill Gallagher¹⁴, David T Dexter¹⁴, Donald G. Grosset¹⁸, Mark Forrest Gordon⁵, Zulfiqar Sheikh Haider⁸, Paul Maguire¹⁷, Alyssa Reimer¹⁰, Emilio Moreno Carretero⁸, Syed Z. Imam⁷, Danna Jennings⁶, Renee Hynds¹, Jonas Weidemann²⁰, Babak Boroojerdi¹⁷, Mark Frasier¹⁰, Dawn Matthews³, Chris Min¹², Sreeraj Macha¹², Pierandrea Muglia¹⁷, Tim Nicholas¹⁵, Arthur Roach¹⁴, Ed Somer⁸, Zhiyong Xie¹⁵, David Russell¹¹, John Seibyl¹¹, Ken Marek¹¹- on behalf of Critical Path for Parkinson’s (CPP) Consortium

Affiliations:

1 – Critical Path Institute
2 – AbbVie Inc
3 – ADM Diagnostics, LLC
4 – Biogen
5 – Served as advisor to CPP
6 – Eli Lilly
7 – U.S. Food and Drug Administration
8 – GE Healthcare
9 – IXICO
10 – Michael J. Fox Foundation
11 – Institute for Neurodegenerative Disorders, Molecular Neuroimaging LLC
12 – Merck & Co. Inc
13 – NIH/NINDS
14 – Parkinson’s UK
15 – Pfizer
16 – F. Hoffmann-La Roche Ltd
17 – UCB Pharma
18 – University of Glasgow
19 – GSK
20 - Lundbeck

Methodological Question: Regulatory endorsement of imaging biomarker in Parkinson’s disease clinical trials targeting early stages of the disease

Objective: A key goal of the Critical Path for Parkinson’s Consortium (CPP) is to achieve regulatory endorsement for drug development tools for use in Parkinson’s disease (PD) clinical trials. CPP’s PD imaging biomarker team aims to achieve regulatory endorsement for the application of reduced dopamine transporter (DAT) binding as a biomarker for PD clinical trial enrichment.

Background: As therapeutic trials target earlier stages PD, appropriate patient selection based purely on clinical criteria poses significant challenges. In the absence of a biomarker, there may
be patients enrolled not suitable for an investigational new drug trial and could potentially jeopardize the trial outcome. Use of biomarkers can enable improved accuracy in selecting appropriate subjects for enrollment in clinical trials and to decrease the enrolment number required to ascertain efficacy.

Methods: A team of pharmaceutical companies, academic key opinion leaders, government agencies and advocacy organizations formally submitted to EMA and FDA documentation supporting the use of DAT SPECT imaging in PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson’s Progression Markers Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor PD.

Results: The presence of reduced striatal DAT binding based on visual reads of SPECT scans in early motor PD subjects is an independent predictor of faster decline in UPDRS Parts II and III as compared to subjects without evidence of dopamine deficiency (SWEDD) over 24 months. The FDA (March 2015) and EMA (October 2016) have issued publicly posted letters of support to encourage collection and sharing of relevant data supporting the use of DAT at baseline as an enrichment biomarker. The EMA is poised to issue in early 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms.

Conclusions: Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical trial populations with idiopathic PD patients, improve statistical power, and spare subjects who are unlikely to have PD from being exposed to novel test therapeutics. Publicly posted letters of support and biomarker qualification issued by global regulatory agencies encourage broader use of this biomarker by trial sponsors.

As Critical Path for Parkinson’s is a precompetitive public private partnership that enables collaborations for which there is no bias for any single stakeholder or product, the authors report no conflicts of interest for this work.